Lymphocyte transformation and autoimmune disorders

Autoimmunity Reviews

Volumn 12, Issue 8, 2013, Pages 802-813

  Tarella, C ^a,b   Gueli, A ^a,b   Ruella, M ^a,b   Cignetti, A ^a,b  

^a MAURIZIANO HOSPITAL   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Autoimmune disorders; Autologous stem cell transplantation; Epidemiology; Lymphomagenesis; Non Hodgkin's lymphoma; Rituximab

Indexed keywords

ADALIMUMAB; APRIL PROTEIN; AZATHIOPRINE; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CORTICOSTEROID; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; RITUXIMAB;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; B LYMPHOCYTE ACTIVATION; CANCER PROGNOSIS; CANCER RISK; CD4 LYMPHOCYTE COUNT; CELIAC DISEASE; CELL CLONE; CLINICAL FEATURE; CROHN DISEASE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE SEDIMENTATION RATE; HEREDITY; HUMAN; HYPOCOMPLEMENTEMIA; IMMUNOSUPPRESSIVE TREATMENT; LARGE CELL LYMPHOMA; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE TRANSFORMATION; LYMPHOCYTOPENIA; MARGINAL ZONE LYMPHOMA; MONOCLONAL IMMUNOGLOBULINEMIA; NONHODGKIN LYMPHOMA; NONHUMAN; PATHOGENESIS; RECOMMENDED DRUG DOSE; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE ACTIVATION; LYMPHOMA, NON-HODGKIN; SJOGREN'S SYNDROME;

EID: 84878539013     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2012.11.004     Document Type: Review

References (204)

1. Jaffe E.S., Harris N.L., Stein H., Isaacson P.G. Classification of lymphoid neoplasms: the microscope as a tool for disease discovery. Blood 2008, 112:4384-4399.
2. Surveillance epidemiology and end results.
3. Zintzaras E., Voulgarelis M., Moutsopoulos H.M. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 2005, 165:2337-2344.
4. Tomer Y., Sherer Y., Shoenfeld Y. Autoantibodies, autoimmunity and cancer (review). Oncol Rep 1998, 5:753-761.
5. Goldin L.R., Landgren O. Autoimmunity and lymphomagenesis. Int J Cancer 2009, 124:1497-1502.
6. Smedby K.E., Askling J., Mariette X., Baecklund E. Autoimmune and inflammatory disorders and risk of malignant lymphomas-an update. J Intern Med 2008, 264:514-527.
7. Martin D.N., Mikhail I.S., Landgren O. Autoimmunity and hematologic malignancies: associations and mechanisms. Leuk Lymphoma 2009, 50:541-550.
8. Jaffe E.S. WHO classification of lymphomas: implications for clinical practice and translational research. Hematology Am Soc Hematol Educ Program 2008, 2009:523-531.
9. Sverdlow S.H.C.E., Harris N.L., et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 2008, IARC press, Lyon. 4th ed.
10. Stern M., Buser A.S., Lohri A., Tichelli A., Nissen-Druey C. Autoimmunity and malignancy in hematology-more than an association. Crit Rev Oncol Hematol 2007, 63:100-110.
11. Anderson L.A., Gadalla S., Morton L.M., Landgren O., Pfeiffer R., Warren J.L., et al. Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies. Int J Cancer 2009, 125:398-405.
12. Smedby K.E., Baecklund E., Askling J. Malignant lymphomas in autoimmunity and inflammation: a review of risks, risk factors, and lymphoma characteristics. Cancer Epidemiol Biomarkers Prev 2006, 15:2069-2077.
13. Bernatsky S., Ramsey-Goldman R., Clarke A. Malignancy and autoimmunity. Curr Opin Rheumatol 2006, 18:129-134.
14. Ansell P., Simpson J., Lightfoot T., Smith A., Kane E., Howell D., et al. Non-Hodgkin lymphoma and autoimmunity: does gender matter?. Int J Cancer 2011, 129:460-466.
15. Dias C., Isenberg D.A. Susceptibility of patients with rheumatic diseases to B-cell non-Hodgkin lymphoma. Nat Rev Rheumatol 2011, 7:360-368.
16. Hansen A., Lipsky P.E., Dorner T. B-cell lymphoproliferation in chronic inflammatory rheumatic diseases. Nat Clin Pract Rheumatol 2007, 3:561-569.
17. Ekstrom Smedby K., Vajdic C.M., Falster M., Engels E.A., Martinez-Maza O., Turner J., et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood 2008, 111:4029-4038.
18. Franklin J., Lunt M., Bunn D., Symmons D., Silman A. Incidence of lymphoma in a large primary care derived cohort of cases of inflammatory polyarthritis. Ann Rheum Dis 2006, 65:617-622.
19. Kiss E., Kovacs L., Szodoray P. Malignancies in systemic lupus erythematosus. Autoimmun Rev 2010, 9:195-199.
20. Tack G.J., Verbeek W.H., Schreurs M.W., Mulder C.J. The spectrum of celiac disease: epidemiology, clinical aspects and treatment. Nat Rev Gastroenterol Hepatol 2010, 7:204-213.
21. Lazarus M.N., Robinson D., Mak V., Moller H., Isenberg D.A. Incidence of cancer in a cohort of patients with primary Sjogren's syndrome. Rheumatology (Oxford) 2006, 45:1012-1015.
22. Kassan S.S., Thomas T.L., Moutsopoulos H.M., Hoover R., Kimberly R.P., Budman D.R., et al. Increased risk of lymphoma in sicca syndrome. Ann Intern Med 1978, 89:888-892.
23. Kauppi M., Pukkala E., Isomaki H. Elevated incidence of hematologic malignancies in patients with Sjogren's syndrome compared with patients with rheumatoid arthritis (Finland). Cancer Causes Control 1997, 8:201-204.
24. Ioannidis J.P., Vassiliou V.A., Moutsopoulos H.M. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjogren's syndrome. Arthritis Rheum 2002, 46:741-747.
25. Masaki Y., Sugai S. Lymphoproliferative disorders in Sjogren's syndrome. Autoimmun Rev 2004, 3:175-182.
26. Varoczy L., Payer E., Kadar Z., Gergely L., Miltenyi Z., Magyari F., et al. Malignant lymphomas and autoimmunity-a single center experience from Hungary. Clin Rheumatol 2012, 31:219-224.
27. Theander E., Manthorpe R., Jacobsson L.T. Mortality and causes of death in primary Sjogren's syndrome: a prospective cohort study. Arthritis Rheum 2004, 50:1262-1269.
28. Engels E.A., Cerhan J.R., Linet M.S., Cozen W., Colt J.S., Davis S., et al. Immune-related conditions and immune-modulating medications as risk factors for non-Hodgkin's lymphoma: a case-control study. Am J Epidemiol 2005, 162:1153-1161.
29. Voulgarelis M., Ziakas P.D., Papageorgiou A., Baimpa E., Tzioufas A.G., Moutsopoulos H.M. Prognosis and outcome of non-Hodgkin lymphoma in primary Sjogren syndrome. Medicine (Baltimore) 2012, 91:1-9.
30. Zhang W., Feng S., Yan S., Zhao Y., Li M., Sun J., et al. Incidence of malignancy in primary Sjogren's syndrome in a Chinese cohort. Rheumatology (Oxford) 2010, 49:571-577.
31. Pertovaara M., Pukkala E., Laippala P., Miettinen A., Pasternack A. A longitudinal cohort study of Finnish patients with primary Sjogren's syndrome: clinical, immunological, and epidemiological aspects. Ann Rheum Dis 2001, 60:467-472.
32. Voulgarelis M., Dafni U.G., Isenberg D.A., Moutsopoulos H.M. Malignant lymphoma in primary Sjogren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjogren's syndrome. Arthritis Rheum 1999, 42:1765-1772.
33. Sutcliffe N., Inanc M., Speight P., Isenberg D. Predictors of lymphoma development in primary Sjogren's syndrome. Semin Arthritis Rheum 1998, 28:80-87.
34. Skopouli F.N., Dafni U., Ioannidis J.P., Moutsopoulos H.M. Clinical evolution, and morbidity and mortality of primary Sjogren's syndrome. Semin Arthritis Rheum 2000, 29:296-304.
35. Tzioufas A.G., Boumba D.S., Skopouli F.N., Moutsopoulos H.M. Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjogren's syndrome. Arthritis Rheum 1996, 39:767-772.
36. Theander E., Henriksson G., Ljungberg O., Mandl T., Manthorpe R., Jacobsson L.T. Lymphoma and other malignancies in primary Sjogren's syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 2006, 65:796-803.
37. Baldini C., Pepe P., Luciano N., Ferro F., Talarico R., Grossi S., et al. A clinical prediction rule for lymphoma development in primary Sjogren's syndrome. J Rheumatol 2012, 39:804-808.
38. Solans-Laque R., Lopez-Hernandez A., Bosch-Gil J.A., Palacios A., Campillo M., Vilardell-Tarres M. Risk, predictors, and clinical characteristics of lymphoma development in primary Sjogren's syndrome. Semin Arthritis Rheum 2011, 41:415-423.
39. Baimpa E., Dahabreh I.J., Voulgarelis M., Moutsopoulos H.M. Hematologic manifestations and predictors of lymphoma development in primary Sjogren syndrome: clinical and pathophysiologic aspects. Medicine (Baltimore) 2009, 88:284-293.
40. Ramos-Casals M., Cervera R., Font J., Garcia-Carrasco M., Espinosa G., Reino S., et al. Young onset of primary Sjogren's syndrome: clinical and immunological characteristics. Lupus 1998, 7:202-206.
41. Pariente D., Anaya J.M., Combe B., Jorgensen C., Emberger J.M., Rossi J.F., et al. Non-Hodgkin's lymphoma associated with primary Sjogren's syndrome. Eur J Med 1992, 1:337-342.
42. Royer B., Cazals-Hatem D., Sibilia J., Agbalika F., Cayuela J.M., Soussi T., et al. Lymphomas in patients with Sjogren's syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites, and are not associated with viruses. Blood 1997, 90:766-775.
43. Hakulinen T., Isomaki H., Knekt P. Rheumatoid arthritis and cancer studies based on linking nationwide registries in Finland. Am J Med 1985, 78:29-32.
44. Mellemkjaer L., Linet M.S., Gridley G., Frisch M., Moller H., Olsen J.H. Rheumatoid arthritis and cancer risk. Eur J Cancer 1996, 32A:1753-1757.
45. Thomas E., Brewster D.H., Black R.J., Macfarlane G.J. Risk of malignancy among patients with rheumatic conditions. Int J Cancer 2000, 88:497-502.
46. Askling J., Fored C.M., Baecklund E., Brandt L., Backlin C., Ekbom A., et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 2005, 64:1414-1420.
47. Zhang Y., Holford T.R., Leaderer B., Zahm S.H., Boyle P., Morton L.M., et al. Prior medical conditions and medication use and risk of non-Hodgkin lymphoma in Connecticut United States women. Cancer Causes Control 2004, 15:419-428.
48. Hemminki K., Li X., Sundquist K., Sundquist J. Cancer risk in hospitalized rheumatoid arthritis patients. Rheumatology (Oxford) 2008, 47:698-701.
49. Gridley G., McLaughlin J.K., Ekbom A., Klareskog L., Adami H.O., Hacker D.G., et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 1993, 85:307-311.
50. Ehrenfeld M., Abu-Shakra M., Buskila D., Shoenfeld Y. The dual association between lymphoma and autoimmunity. Blood Cells Mol Dis 2001, 27:750-756.
51. Mariette X., Gottenberg J.E., Ravaud P., Combe B. Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries. Rheumatology (Oxford) 2011, 50:222-229.
52. Baecklund E., Backlin C., Iliadou A., Granath F., Ekbom A., Amini R.M., et al. Characteristics of diffuse large B cell lymphomas in rheumatoid arthritis. Arthritis Rheum 2006, 54:3774-3781.
53. Ekstrom K., Hjalgrim H., Brandt L., Baecklund E., Klareskog L., Ekbom A., et al. Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives. Arthritis Rheum 2003, 48:963-970.
54. Gridley G., Klippel J.H., Hoover R.N., Fraumeni J.F. Incidence of cancer among men with the Felty syndrome. Ann Intern Med 1994, 120:35-39.
55. Baecklund E., Ekbom A., Sparen P., Feltelius N., Klareskog L. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ 1998, 317:180-181.
56. Bongartz T., Sutton A.J., Sweeting M.J., Buchan I., Matteson E.L., Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006, 295:2275-2285.
57. Wong A.K., Kerkoutian S., Said J., Rashidi H., Pullarkat S.T. Risk of lymphoma in patients receiving antitumor necrosis factor therapy: a meta-analysis of published randomized controlled studies. Clin Rheumatol 2012, 31:631-636.
58. Baecklund E., Natkunam Y., Backlin C., Iliadou A., Askling J., Ekbom A., et al. Expression of the human germinal-centre-associated lymphoma protein in diffuse large B-cell lymphomas in patients with rheumatoid arthritis. Br J Haematol 2008, 141:69-72.
59. Brown L.M., Gridley G., Check D., Landgren O. Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders. Blood 2008, 111:3388-3394.
60. Landgren O., Engels E.A., Pfeiffer R.M., Gridley G., Mellemkjaer L., Olsen J.H., et al. Autoimmunity and susceptibility to Hodgkin lymphoma: a population-based case-control study in Scandinavia. J Natl Cancer Inst 2006, 98:1321-1330.
61. Landgren O., Gridley G., Check D., Caporaso N.E., Morris Brown L. Acquired immune-related and inflammatory conditions and subsequent chronic lymphocytic leukaemia. Br J Haematol 2007, 139:791-798.
62. Landgren O., Linet M.S., McMaster M.L., Gridley G., Hemminki K., Goldin L.R. Familial characteristics of autoimmune and hematologic disorders in 8,406 multiple myeloma patients: a population-based case-control study. Int J Cancer 2006, 118:3095-3098.
63. Bernatsky S., Ramsey-Goldman R., Rajan R., Boivin J.F., Joseph L., Lachance S., et al. Non-Hodgkin's lymphoma in systemic lupus erythematosus. Ann Rheum Dis 2005, 64:1507-1509.
64. Vineis P., Crosignani P., Sacerdote C., Fontana A., Masala G., Miligi L., et al. Haematopoietic cancer and medical history: a multicentre case control study. J Epidemiol Community Health 2000, 54:431-436.
65. Cibere J., Sibley J., Haga M. Systemic lupus erythematosus and the risk of malignancy. Lupus 2001, 10:394-400.
66. Xu Y., Wiernik P.H. Systemic lupus erythematosus and B-cell hematologic neoplasm. Lupus 2001, 10:841-850.
67. Ragnarsson O., Grondal G., Steinsson K. Risk of malignancy in an unselected cohort of Icelandic patients with systemic lupus erythematosus. Lupus 2003, 12:687-691.
68. Bernatsky S., Ramsey-Goldman R., Isenberg D., Rahman A., Dooley M.A., Sibley J., et al. Hodgkin's lymphoma in systemic lupus erythematosus. Rheumatology (Oxford) 2007, 46:830-832.
69. Ramsey-Goldman R., Mattai S.A., Schilling E., Chiu Y.L., Alo C.J., Howe H.L., et al. Increased risk of malignancy in patients with systemic lupus erythematosus. J Investig Med 1998, 46:217-222.
70. Mellemkjaer L., Andersen V., Linet M.S., Gridley G., Hoover R., Olsen J.H. Non-Hodgkin's lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus. Arthritis Rheum 1997, 40:761-768.
71. Abu-Shakra M., Gladman D.D., Urowitz M.B. Malignancy in systemic lupus erythematosus. Arthritis Rheum 1996, 39:1050-1054.
72. Bjornadal L., Lofstrom B., Yin L., Lundberg I.E., Ekbom A. Increased cancer incidence in a Swedish cohort of patients with systemic lupus erythematosus. Scand J Rheumatol 2002, 31:66-71.
73. Mellemkjaer L., Pfeiffer R.M., Engels E.A., Gridley G., Wheeler W., Hemminki K., et al. Autoimmune disease in individuals and close family members and susceptibility to non-Hodgkin's lymphoma. Arthritis Rheum 2008, 58:657-666.
74. Bernatsky S., Boivin J.F., Joseph L., Rajan R., Zoma A., Manzi S., et al. An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum 2005, 52:1481-1490.
75. Dreyer L., Faurschou M., Mogensen M., Jacobsen S. High incidence of potentially virus-induced malignancies in systemic lupus erythematosus: a long-term follow-up study in a Danish cohort. Arthritis Rheum 2011, 63:3032-3037.
76. Chen Y.J., Chang Y.T., Wang C.B., Wu C.Y. Malignancy in systemic lupus erythematosus: a nationwide cohort study in Taiwan. Am J Med 2010, 123:1150. [e1-6].
77. Lofstrom B., Backlin C., Sundstrom C., Ekbom A., Lundberg I.E. A closer look at non-Hodgkin's lymphoma cases in a national Swedish systemic lupus erythematosus cohort: a nested case-control study. Ann Rheum Dis 2007, 66:1627-1632.
78. Bernatsky S., Joseph L., Boivin J.F., Gordon C., Urowitz M., Gladman D., et al. The relationship between cancer and medication exposures in systemic lupus erythaematosus: a case-cohort study. Ann Rheum Dis 2008, 67:74-79.
79. Sigurgeirsson B., Agnarsson B.A., Lindelof B. Risk of lymphoma in patients with dermatitis herpetiformis. BMJ 1994, 308:13-15.
80. Collin P., Pukkala E., Reunala T. Malignancy and survival in dermatitis herpetiformis: a comparison with coeliac disease. Gut 1996, 38:528-530.
81. Askling J., Brandt L., Lapidus A., Karlen P., Bjorkholm M., Lofberg R., et al. Risk of haematopoietic cancer in patients with inflammatory bowel disease. Gut 2005, 54:617-622.
82. Catassi C., Fabiani E., Corrao G., Barbato M., De Renzo A., Carella A.M., et al. Risk of non-Hodgkin lymphoma in celiac disease. JAMA 2002, 287:1413-1419.
83. West J., Logan R.F., Smith C.J., Hubbard R.B., Card T.R. Malignancy and mortality in people with coeliac disease: population based cohort study. BMJ 2004, 329:716-719.
84. Silano M., Volta U., Mecchia A.M., Dessi M., Di Benedetto R., De Vincenzi M. Delayed diagnosis of coeliac disease increases cancer risk. BMC Gastroenterol 2007, 7:8.
85. Kato I., Tajima K., Suchi T., Aozasa K., Matsuzuka F., Kuma K., et al. Chronic thyroiditis as a risk factor of B-cell lymphoma in the thyroid gland. Jpn J Cancer Res 1985, 76:1085-1090.
86. Holm L.E., Blomgren H., Lowhagen T. Cancer risks in patients with chronic lymphocytic thyroiditis. N Engl J Med 1985, 312:601-604.
87. Anderson L.A., McMillan S.A., Watson R.G., Monaghan P., Gavin A.T., Fox C., et al. Malignancy and mortality in a population-based cohort of patients with coeliac disease or "gluten sensitivity". World J Gastroenterol 2007, 13:146-151.
88. Askling J., Linet M., Gridley G., Halstensen T.S., Ekstrom K., Ekbom A. Cancer incidence in a population-based cohort of individuals hospitalized with celiac disease or dermatitis herpetiformis. Gastroenterology 2002, 123:1428-1435.
89. Card T.R., West J., Holmes G.K. Risk of malignancy in diagnosed coeliac disease: a 24-year prospective, population-based, cohort study. Aliment Pharmacol Ther 2004, 20:769-775.
90. Catassi C., Bearzi I., Holmes G.K. Association of celiac disease and intestinal lymphomas and other cancers. Gastroenterology 2005, 128:S79-S86.
91. Goldacre M.J., Wotton C.J., Yeates D., Seagroatt V., Jewell D. Cancer in patients with ulcerative colitis, Crohn's disease and coeliac disease: record linkage study. Eur J Gastroenterol Hepatol 2008, 20:297-304.
92. Green P.H., Fleischauer A.T., Bhagat G., Goyal R., Jabri B., Neugut A.I. Risk of malignancy in patients with celiac disease. Am J Med 2003, 115:191-195.
93. Holmes G.K., Prior P., Lane M.R., Pope D., Allan R.N. Malignancy in coeliac disease-effect of a gluten free diet. Gut 1989, 30:333-338.
94. Holmes G.K., Stokes P.L., Sorahan T.M., Prior P., Waterhouse J.A., Cooke W.T. Coeliac disease, gluten-free diet, and malignancy. Gut 1976, 17:612-619.
95. Swinson C.M., Slavin G., Coles E.C., Booth C.C. Coeliac disease and malignancy. Lancet 1983, 1:111-115.
96. Viljamaa M., Kaukinen K., Pukkala E., Hervonen K., Reunala T., Collin P. Malignancies and mortality in patients with coeliac disease and dermatitis herpetiformis: 30-year population-based study. Dig Liver Dis 2006, 38:374-380.
97. Gao Y., Kristinsson S.Y., Goldin L.R., Bjorkholm M., Caporaso N.E., Landgren O. Increased risk for non-Hodgkin lymphoma in individuals with celiac disease and a potential familial association. Gastroenterology 2009, 136:91-98.
98. Smedby K.E., Akerman M., Hildebrand H., Glimelius B., Ekbom A., Askling J. Malignant lymphomas in coeliac disease: evidence of increased risks for lymphoma types other than enteropathy-type T cell lymphoma. Gut 2005, 54:54-59.
99. Jones J.L., Loftus E.V. Lymphoma risk in inflammatory bowel disease: is it the disease or its treatment?. Inflamm Bowel Dis 2007, 13:1299-1307.
100. Loftus E.V., Tremaine W.J., Habermann T.M., Harmsen W.S., Zinsmeister A.R., Sandborn W.J. Risk of lymphoma in inflammatory bowel disease. Am J Gastroenterol 2000, 95:2308-2312.
101. Bernstein C.N., Blanchard J.F., Kliewer E., Wajda A. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 2001, 91:854-862.
102. Hemminki K., Li X., Sundquist J., Sundquist K. Cancer risks in Crohn disease patients. Ann Oncol 2009, 20:574-580.
103. Lewis J.D., Bilker W.B., Brensinger C., Deren J.J., Vaughn D.J., Strom B.L. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology 2001, 121:1080-1087.
104. Jess T., Winther K.V., Munkholm P., Langholz E., Binder V. Intestinal and extra-intestinal cancer in Crohn's disease: follow-up of a population-based cohort in Copenhagen County, Denmark. Aliment Pharmacol Ther 2004, 19:287-293.
105. Pedersen N., Duricova D., Elkjaer M., Gamborg M., Munkholm P., Jess T. Risk of extra-intestinal cancer in inflammatory bowel disease: meta-analysis of population-based cohort studies. Am J Gastroenterol 2010, 105:1480-1487.
106. Ekbom A., Helmick C., Zack M., Adami H.O. Extracolonic malignancies in inflammatory bowel disease. Cancer 1991, 67:2015-2019.
107. Persson P.G., Karlen P., Bernell O., Leijonmarck C.E., Brostrom O., Ahlbom A., et al. Crohn's disease and cancer: a population-based cohort study. Gastroenterology 1994, 107:1675-1679.
108. Palli D., Trallori G., Bagnoli S., Saieva C., Tarantino O., Ceroti M., et al. Hodgkin's disease risk is increased in patients with ulcerative colitis. Gastroenterology 2000, 119:647-653.
109. Sokol H., Beaugerie L. Inflammatory bowel disease and lymphoproliferative disorders: the dust is starting to settle. Gut 2009, 58:1427-1436.
110. Lichtenstein G.R., Feagan B.G., Cohen R.D., Salzberg B.A., Diamond R.H., Chen D.M., et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006, 4:621-630.
111. Peyrin-Biroulet L., Deltenre P., de Suray N., Branche J., Sandborn W.J., Colombel J.F. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008, 6:644-653.
112. Lichtenstein G.R., Feagan B.G., Cohen R.D., Salzberg B.A., Diamond R.H., Price S., Langholff W., Londhe A., Sandborn W.J. Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry. Am J Gastroenterol 2012, 107(9):1409-1422.
113. Beaugerie L., Brousse N., Bouvier A.M., Colombel J.F., Lemann M., Cosnes J., et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009, 374:1617-1625.
114. Siegel C.A., Marden S.M., Persing S.M., Larson R.J., Sands B.E. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol 2009, 7:874-881.
115. Mackey A.C., Green L., Leptak C., Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update. J Pediatr Gastroenterol Nutr 2009, 48:386-388.
116. Kotlyar D.S., Osterman M.T., Diamond R.H., Porter D., Blonski W.C., Wasik M., et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2011, 9:36-41. [e1].
117. Nogai H., Dorken B., Lenz G. Pathogenesis of non-Hodgkin's lymphoma. J Clin Oncol 2011, 29:1803-1811.
118. Youinou P. Is BAFF the murderer in lupus?. Lupus 2008, 17:613-614.
119. Tangye S.G., Bryant V.L., Cuss A.K., Good K.L. BAFF, APRIL and human B cell disorders. Semin Immunol 2006, 18:305-317.
120. Lofstrom B., Backlin C., Pettersson T., Lundberg I.E., Baecklund E. Expression of APRIL in diffuse large B cell lymphomas from patients with systemic lupus erythematosus and rheumatoid arthritis. J Rheumatol 2011, 38:1891-1897.
121. Mackay F., Tangye S.G. The role of the BAFF/APRIL system in B cell homeostasis and lymphoid cancers. Curr Opin Pharmacol 2004, 4:347-354.
122. Vereecke L., Beyaert R., van Loo G. The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology. Trends Immunol 2009, 30:383-391.
123. Chanudet E., Huang Y., Ichimura K., Dong G., Hamoudi R.A., Radford J., et al. A20 is targeted by promoter methylation, deletion and inactivating mutation in MALT lymphoma. Leukemia 2010, 24:483-487.
124. Chanudet E., Ye H., Ferry J., Bacon C.M., Adam P., Muller-Hermelink H.K., et al. A20 deletion is associated with copy number gain at the TNFA/B/C locus and occurs preferentially in translocation-negative MALT lymphoma of the ocular adnexa and salivary glands. J Pathol 2009, 217:420-430.
125. Chanudet E., Huang Y., Zeng N., Streubel B., Chott A., Raderer M., et al. TNFAIP3 abnormalities in MALT lymphoma with autoimmunity. Br J Haematol 2011, 154:535-539.
126. Mackay I.R., Rose N.R. Autoimmunity and lymphoma: tribulations of B cells. Nat Immunol 2001, 2:793-795.
127. Hayter S.M., Cook M.C. Updated assessment of the prevalence, spectrum and case definition of autoimmune disease. Autoimmun Rev Aug 2012, 11(10):754-765. [Epub 2012 Feb 23]. 10.1016/j.autrev.2012.02.001.
128. Firestein G.S. Evolving concepts of rheumatoid arthritis. Nature 2003, 423:356-361.
129. Bernatsky S., Clarke A., Ramsey-Goldman R. Malignancy and systemic lupus erythematosus. Curr Rheumatol Rep 2002, 4:351-358.
130. Di Sabatino Antonio, Vanoli Alessandro, Giuffrida Paolo, Luinetti Ombretta, Solcia Enrico, Roberto Corazza Gino The function of tissue transglutaminase in celiac disease. Autoimmun Rev 2012, [ISSN 1568-9972, http://dx.doi.org/10.1016/j.autrev.2012.01.007].
131. Yamamoto K. Pathogenesis of Sjogren's syndrome. Autoimmun Rev 2003, 2:13-18.
132. Chiorazzi N., Rai K.R., Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005, 352:804-815.
133. Baecklund E., Askling J., Rosenquist R., Ekbom A., Klareskog L. Rheumatoid arthritis and malignant lymphomas. Curr Opin Rheumatol 2004, 16:254-261.
134. Cellier C., Delabesse E., Helmer C., Patey N., Matuchansky C., Jabri B., et al. Refractory sprue, coeliac disease, and enteropathy-associated T-cell lymphoma. Lancet 2000, 356:203-208.
135. Engels E.A. Infectious agents as causes of non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev 2007, 16:401-404.
136. Engels E.A., Chatterjee N., Cerhan J.R., Davis S., Cozen W., Severson R.K., et al. Hepatitis C virus infection and non-Hodgkin lymphoma: results of the NCI-SEER multi-center case-control study. Int J Cancer 2004, 111:76-80.
137. Giordano T.P., Henderson L., Landgren O., Chiao E.Y., Kramer J.R., El-Serag H., et al. Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA 2007, 297:2010-2017.
138. Jaffe E.S. Lymphoid lesions of the head and neck: a model of lymphocyte homing and lymphomagenesis. Mod Pathol 2002, 15:255-263.
139. Bahler D.W., Swerdlow S.H. Clonal salivary gland infiltrates associated with myoepithelial sialadenitis (Sjogren's syndrome) begin as nonmalignant antigen-selected expansions. Blood 1998, 91:1864-1872.
140. Fox R.I. Sjogren's syndrome. Lancet 2005, 366:321-331.
141. Salomonsson S., Jonsson M.V., Skarstein K., Brokstad K.A., Hjelmstrom P., Wahren-Herlenius M., et al. Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sjogren's syndrome. Arthritis Rheum 2003, 48:3187-3201.
142. Du M., Diss T.C., Xu C., Peng H., Isaacson P.G., Pan L. Ongoing mutation in MALT lymphoma immunoglobulin gene suggests that antigen stimulation plays a role in the clonal expansion. Leukemia 1996, 10:1190-1197.
143. Kamel O.W., Holly E.A., van de Rijn M., Lele C., Sah A. A population based, case control study of non-Hodgkin's lymphoma in patients with rheumatoid arthritis. J Rheumatol 1999, 26:1676-1680.
144. Wolfe F., Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004, 50:1740-1751.
145. Ambinder R.F. Epstein-Barr virus-associated lymphoproliferative disorders. Rev Clin Exp Hematol 2003, 7:362-374.
146. Young L.S., Rickinson A.B. Epstein-Barr virus: 40years on. Nat Rev Cancer 2004, 4:757-768.
147. Mariette X., Cazals-Hatem D., Warszawki J., Liote F., Balandraud N., Sibilia J. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood 2002, 99:3909-3915.
148. Baecklund E., Sundstrom C., Ekbom A., Catrina A.I., Biberfeld P., Feltelius N., et al. Lymphoma subtypes in patients with rheumatoid arthritis: increased proportion of diffuse large B cell lymphoma. Arthritis Rheum 2003, 48:1543-1550.
149. Hoshida Y., Xu J.X., Fujita S., Nakamichi I., Ikeda J., Tomita Y., et al. Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. J Rheumatol 2007, 34:322-331.
150. Kaiser R. Incidence of lymphoma in patients with rheumatoid arthritis: a systematic review of the literature. Clin Lymphoma Myeloma 2008, 8:87-93.
151. Geborek P., Bladstrom A., Turesson C., Gulfe A., Petersson I.F., Saxne T., et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 2005, 64:699-703.
152. Wolfe F., Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710person-years of observation. Arthritis Rheum 2007, 56:1433-1439.
153. Keystone E.C. Does anti-tumor necrosis factor-alpha therapy affect risk of serious infection and cancer in patients with rheumatoid arthritis?: a review of longterm data. J Rheumatol 2011, 38:1552-1562.
154. Rosenblum H., Amital H. Anti-TNF therapy: safety aspects of taking the risk. Autoimmun Rev 2011, 10:563-568.
155. Gatto M., Zen M., Ghirardello A., Bettio S., et al. Emerging and critical issues in the pathogenesis of lupus. Autoimmun Rev Sep 18 2012, [doi:pii:S1568-9972(12)002133, http://dx.doi.org/10.1016/j.autrev.2012.09.003. [Epub ahead of print]].
156. Pisetsky D.S. The role of innate immunity in the induction of autoimmunity. Autoimmun Rev 2008, 8:69-72.
157. Banchereau J., Pascual V. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 2006, 25:383-392.
158. Veeranki S., Choubey D. Systemic lupus erythematosus and increased risk to develop B cell malignancies: role of the p200-family proteins. Immunol Lett 2010, 133:1-5.
159. Choubey D., Deka R., Ho S.M. Interferon-inducible IFI16 protein in human cancers and autoimmune diseases. Front Biosci 2008, 13:598-608.
160. Moss K.E., Ioannou Y., Sultan S.M., Haq I., Isenberg D.A. Outcome of a cohort of 300 patients with systemic lupus erythematosus attending a dedicated clinic for over two decades. Ann Rheum Dis 2002, 61:409-413.
161. Pettersson T., Pukkala E., Teppo L., Friman C. Increased risk of cancer in patients with systemic lupus erythematosus. Ann Rheum Dis 1992, 51:437-439.
162. Bernatsky S., Kale M., Ramsey-Goldman R., Gordon C., Clarke A.E. Systemic lupus and malignancies. Curr Opin Rheumatol 2012, 24:177-181.
163. Evans L.S., Hancock B.W. Non-Hodgkin lymphoma. Lancet 2003, 362:139-146.
164. Mikuls T.R., Endo J.O., Puumala S.E., Aoun P.A., Black N.A., O'Dell J.R., et al. Prospective study of survival outcomes in Non-Hodgkin's lymphoma patients with rheumatoid arthritis. J Clin Oncol 2006, 24:1597-1602.
165. Illes A., Varoczy L., Papp G., Wilson P.C., Alex P., Jonsson R., et al. Aspects of B-cell non-Hodgkin's lymphoma development: a transition from immune-reactivity to malignancy. Scand J Immunol 2009, 69:387-400.
166. Simon Z., Tarr T., Ress Z., Gergely L., Kiss E., Illes A. Successful rituximab-CHOP treatment of systemic lupus erythematosus associated with diffuse large B-cell non-Hodgkin lymphoma. Rheumatol Int 2007, 28:179-183.
167. Bernatsky S., Boivin J.F., Joseph L., Manzi S., Ginzler E., Gladman D.D., et al. Mortality in systemic lupus erythematosus. Arthritis Rheum 2006, 54:2550-2557.
168. Sehn L.H., Donaldson J., Chhanabhai M., Fitzgerald C., Gill K., Klasa R., et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005, 23:5027-5033.
169. Coiffier B., Lepage E., Briere J., Herbrecht R., Tilly H., Bouabdallah R., et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002, 346:235-242.
170. Forstpointner R., Dreyling M., Repp R., Hermann S., Hanel A., Metzner B., et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004, 104:3064-3071.
171. Marcus R., Imrie K., Belch A., Cunningham D., Flores E., Catalano J., et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005, 105:1417-1423.
172. Tarella C., Zanni M., Magni M., Benedetti F., Patti C., Barbui T., et al. Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey. J Clin Oncol 2008, 26:3166-3175.
173. Kattah A.G., Fervenza F.C., Roccatello D. Rituximab-based novel strategies for the treatment of immune-mediated glomerular diseases. Autoimmun Rev Sep 19 2012, [doi:pii: S1568-9972(12)00212-1, http://dx.doi.org/10.1016/j.autrev.2012.09.002].
174. Leandro M.J., de la Torre I. Translational mini-review Series on B cell-directed therapies: the pathogenic role of B cells in autoantibody-associated autoimmune diseases-lessons from B cell-depletion therapy. Clin Exp Immunol 2009, 157:191-197.
175. Looney R.J., Anolik J.H., Campbell D., Felgar R.E., Young F., Arend L.J., et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004, 50:2580-2589.
176. Lund F.E. Cytokine-producing B, lymphocytes-key regulators of immunity. Curr Opin Immunol 2008, 20:332-338.
177. Pijpe J., van Imhoff G.W., Spijkervet F.K., Roodenburg J.L., Wolbink G.J., Mansour K., et al. Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study. Arthritis Rheum 2005, 52:2740-2750.
178. Seror R., Sordet C., Guillevin L., Hachulla E., Masson C., Ittah M., et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren's syndrome. Ann Rheum Dis 2007, 66:351-357.
179. Devauchelle-Pensec V., Pennec Y., Morvan J., Pers J.O., Daridon C., Jousse-Joulin S., et al. Improvement of Sjogren's syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum 2007, 57:310-317.
180. Meijer J.M., Meiners P.M., Vissink A., Spijkervet F.K., Abdulahad W., Kamminga N., et al. Effectiveness of rituximab treatment in primary Sjogren's syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010, 62:960-968.
181. Meiners P.M., Vissink A., Kallenberg C.G., Kroese F.G., Bootsma H. Treatment of primary Sjogren's syndrome with anti-CD20 therapy (rituximab). A feasible approach or just a starting point?. Expert Opin Biol Ther 2011, 11:1381-1394.
182. Edwards J.C., Szczepanski L., Szechinski J., Filipowicz-Sosnowska A., Emery P., Close D.R., et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004, 350:2572-2581.
183. Emery P., Fleischmann R., Filipowicz-Sosnowska A., Schechtman J., Szczepanski L., Kavanaugh A., et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006, 54:1390-1400.
184. Cohen S.B., Emery P., Greenwald M.W., Dougados M., Furie R.A., Genovese M.C., et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006, 54:2793-2806.
185. Gurcan H.M., Keskin D.B., Stern J.N., Nitzberg M.A., Shekhani H., Ahmed A.R. A review of the current use of rituximab in autoimmune diseases. Int Immunopharmacol 2009, 9:10-25.
186. Smolen J.S., Keystone E.C., Emery P., Breedveld F.C., Betteridge N., Burmester G.R., et al. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2007, 66:143-150.
187. Emery P., Deodhar A., Rigby W.F., Isaacs J.D., Combe B., Racewicz A.J., et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis 2010, 69:1629-1635.
188. Haraoui B., Bokarewa M., Kallmeyer I., Bykerk V.P. Safety and effectiveness of rituximab in patients with rheumatoid arthritis following an inadequate response to 1 prior tumor necrosis factor inhibitor: the RESET Trial. J Rheumatol 2011, 38:2548-2556.
189. Smith K.G., Jones R.B., Burns S.M., Jayne D.R. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum 2006, 54:2970-2982.
190. Tanaka Y., Yamamoto K., Takeuchi T., Nishimoto N., Miyasaka N., Sumida T., et al. A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. Mod Rheumatol 2007, 17:191-197.
191. Merrill J.T., Neuwelt C.M., Wallace D.J., Shanahan J.C., Latinis K.M., Oates J.C., et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010, 62:222-233.
192. Rovin B.H., Furie R., Latinis K., Looney R.J., Fervenza F.C., Sanchez-Guerrero J., et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012, 64:1215-1226.
193. Lu T.Y., Ng K.P., Cambridge G., Leandro M.J., Edwards J.C., Ehrenstein M., et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum 2009, 61:482-487.
194. Ramos-Casals M., Soto M.J., Cuadrado M.J., Khamashta M.A. Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases. Lupus 2009, 18:767-776.
195. Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005, 31:456-473.
196. Fleischmann R.M. Safety of biologic therapy in rheumatoid arthritis and other autoimmune diseases: focus on rituximab. Semin Arthritis Rheum 2009, 38:265-280.
197. Stiff P.J. Blood and marrow transplantation in relapsed or refractory non-Hodgkin's lymphoma. Oncology (Williston Park) 1998, 12:56-62.
198. Gisselbrecht C., Mounier N. Improving second-line therapy in aggressive non-Hodgkin's lymphoma. Semin Oncol 2004, 31:12-16.
199. Van Besien K. The evolving role of autologous and allogeneic stem cell transplantation in follicular lymphoma. Blood Rev 2006, 20:235-244.
200. Tarella C., Passera R., Magni M., Benedetti F., Rossi A., Gueli A., et al. Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma. J Clin Oncol 2011, 29:814-824.
201. Muraro P.A., Douek D.C., Packer A., Chung K., Guenaga F.J., Cassiani-Ingoni R., et al. Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J Exp Med 2005, 201:805-816.
202. Pavletic S.Z. HSCT for AID: entering prime time?. Blood 2011, 118:1438-1439.
203. Atkins H.L., Muraro P.A., van Laar J.M., Pavletic S.Z. Autologous hematopoietic stem cell transplantation for autoimmune disease-is it now ready for prime time?. Biol Blood Marrow Transplant 2012, 18:S177-S183.
204. Farge D., Labopin M., Tyndall A., Fassas A., Mancardi G.L., Van Laar J., et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases. Haematologica 2010, 95:284-292.